Status:

RECRUITING

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Lead Sponsor:

argenx

Conditions:

AChR-Ab Seropositive Generalized Myasthenia Gravis

Myasthenia Gravis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myas...

Detailed Description

Once the master protocol and ISA1 screening periods are completed, eligible participants can enroll in the run-in period (part A) where they will receive efgartigimod IV. Eligible participants can the...

Eligibility Criteria

Inclusion Criteria:

  • Is seropositive for anti-acetylcholine receptor antibodies (AChR-Ab)
  • Has confirmed diagnosis of gMG and is Myasthenia Gravis Foundation of America (MGFA) Class II, III, IVa, or IVb
  • Has documented immunization against encapsulated bacterial pathogens (Neisseria meningitidis and Streptococcus pneumoniae) within 5 years of ISA screening or is willing to receive immunization at least 14 days before the first study drug administration

Exclusion Criteria:

  • Clinical diagnosis of systemic lupus erythematosus (SLE)
  • Any known complement deficiency
  • Current administration of a complement inhibitor or received zilucoplan or eculizumab <2 months or ravulizumab <6 months before the first study drug administration
  • Patients proven to be refractory to efgartigimod (ie, not achieving a clinically meaningful improvement in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score defined as an improvement of ≥2 points)

Key Trial Info

Start Date :

December 19 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 7 2028

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT07284420

Start Date

December 19 2025

End Date

March 7 2028

Last Update

February 9 2026

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Profound Research LLC - Carlsbad

Carlsbad, California, United States, 92011

2

Visionary Investigators Network

Miami, Florida, United States, 33176

3

Dent Neurologic Institute - Amherst

Amherst, New York, United States, 14226

4

Erlanger Health System

Chattanooga, Tennessee, United States, 37403